Phase III long-term open-label safety study of BR005-036C for acute treatment of migraine in adults

Phase 3, open-label, single-arm trial of BR005-036C in migraine, sponsored by Xiyuan Biotech. Primary endpoint: Incidence of treatment-emergent adverse events occurring in at least 5% of participants, severity of adverse events, incidence of serious adverse events, adverse events leading to treatment… Started Sep 2026; status: active.